

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



東北虎藥業股份有限公司  
**NORTHEAST TIGER PHARMACEUTICAL CO., LTD.\***  
*(A joint stock limited company incorporated in the People's Republic of China)*  
(Stock Code: 8197)

## COMPLETION OF THE PLACING OF H-SHARES

Reference is made to the Company's announcements dated 24 May 2016, 27 May 2016, 24 August 2016 and 9 September 2016 (the "Announcements") relating to the Placing. Terms used herein shall have the same meanings as defined in the Announcements unless otherwise stated.

### COMPLETION OF THE PLACING

The Board is pleased to announce that all the conditions as set out in the Placing Agreement and Supplemental Agreement (collectively, the "Agreements") have been satisfied and the Placing was completed on 20 September 2016 in accordance with the terms and conditions of the Agreements. An aggregate of 41,400,000 H-Shares, representing approximately 16.67% and 5.25%, respectively, of the total issued H-Shares and the total issued Shares of the Company as enlarged by the issue of the Placing Shares, have been successfully allotted and issued by the Company at the Placing Price of HK\$0.97 per H-Share to no less than six Placees, who and whose ultimate beneficial owners are third parties independent of and not connected with the Company or its connected persons. None of the Placees has become a substantial shareholder of the Company immediately after the completion of the Placing.

The aggregate gross proceeds from the Placing amount to approximately HK\$40,158,000 (approximately RMB34,471,000) and the aggregate net proceeds from the Placing (after deducting all applicable costs and expenses, including commission and levies) are expected to amount to approximately HK\$38,158,000 (approximately RMB32,754,000).

As a result of the Placing, the total number of issued Shares of the Company has increased from 746,654,240 Shares to 788,054,240 Shares and the total number of H-Shares in issue have increased from 207,000,000 H-Shares to 248,400,000 H-Shares. Set out below is the shareholding structure of the Company (i) immediately before completion of the Placing, and (ii) immediately after completion of the Placing:

	<b>Immediately before completion of the Placing</b>		<b>Immediately after completion of the Placing</b>	
	<i>Number of Shares</i>	<i>Approximate % of issued Shares</i>	<i>Number of Shares</i>	<i>Approximate % of issued Shares</i>
<b>Domestic Shares</b>				
Beijing Bao Ying				
Chuang Fu Investment Management Centre*	398,534,660	53.38	398,534,660	50.57
Guo Feng	137,611,830	18.43	137,611,830	17.46
Zhang Ya Bin	1,618,960	0.22	1,618,960	0.21
Other Shareholders	1,888,790	0.25	1,888,790	0.24
<b>H-Shares</b>				
Public Shareholders	207,000,000	27.72	207,000,000	26.27
Placees	—	—	41,400,000	5.25
<b>Total</b>	<b>746,654,240</b>	<b>100.00</b>	<b>788,054,240</b>	<b>100.00</b>

*Note:* The figures are calculated based on the middle exchange rate of RMB0.8584 to HK\$1 as quoted by The People's Bank of China as at 20 September 2016, being the date of this announcement.

By Order of the Board  
 東北虎藥業股份有限公司  
**Northeast Tiger Pharmaceutical Co., Ltd.\***  
*Chairman*  
**Wang Shaoyan**

Jilin, the PRC, 20 September 2016

*As at the date of this announcement, the Company's executive directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the Company's non-executive directors are Guo Aiqun and Cao Yang and the Company's independent non-executive directors are Zhao Zhen Xing, Chen Youfang and Hui Lai Yam.*

*This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

\* *for identification purposes only*